Navigation Links
Claritin(R) Renews Sponsorship With Allergy Sufferer and NASCAR Star Carl Edwards
Date:2/12/2009

- Partnership Drives Home Importance of Being Alert and Focused on and off the Racetrack -

KENILWORTH, N.J., Feb. 12 /PRNewswire-FirstCall/ -- Schering-Plough (NYSE: SGP), maker of the top-selling allergy medicine, CLARITIN, announces its second Sprint Cup racing season as a sponsor of NASCAR star and long-time allergy sufferer Carl Edwards. Edwards, who takes non-drowsy CLARITIN to treat his allergy symptoms, will drive the No. 99 CLARITIN Ford Fusion during the April NASCAR Sprint Cup race at Talladega Superspeedway, NASCAR's most competitive track.

(Photo: http://www.newscom.com/cgi-bin/prnh/20090212/NY69974 )

"As a driver who races at speeds up to 180 miles an hour, I can't risk taking an allergy medicine that might make me drowsy," said Edwards. "I've continued my partnership with CLARITIN because it works hard to relieve my worst allergy symptoms without drowsiness, so I can think and react fast."

Last year, Edwards was runner-up in both the 2008 NASCAR Sprint Cup Series and NASCAR Nationwide Series point standings. He also was the voice of the CLARITIN Clear To Drive(SM) campaign which emphasizes the importance of reading medicine labels to check for warnings about drowsiness before getting behind the wheel of a car.

"We are thrilled to continue our relationship with Carl Edwards, and we're proud of his accomplishments," said TJ Higgins, Group Vice President, Marketing, Schering-Plough Consumer HealthCare. "Carl has been instrumental in letting consumers know that CLARITIN effectively relieves both indoor and outdoor allergy symptoms without drowsiness and is safe to take when driving."

For more information on allergies and treatments, visit www.CLARITIN.com.

About CLARITIN(R)

All CLARITIN(R) brand products are available without a prescription, including: CLARITIN(R) Tablets, a once-daily, full prescription strength, non-drowsy formulation; CLARITIN(R) RediTabs(R) Tablets, a novel once-daily formulation in a quickly dissolving tablet for ages 6 and older; CLARITIN(R) Liqui-Gels(R), a once-daily formulation in an easy-to-swallow liquid-filled capsule; CLARITIN-D(R) 24-hour and 12-hour Extended Release Tablets, with the decongestant pseudoephedrine, now located behind the counter; CHILDREN'S CLARITIN(R) Syrup, a liquid formulation for children ages 2 and older in grape and fruit flavors; and CHILDREN'S CLARITIN(R) Grape Chewables, a chewable tablet for children ages 2 and older.

CLARITIN(R) is the No. 1 physician-recommended and pediatrician-recommended non-drowsy over-the-counter allergy brand. The CLARITIN(R) Rx-to-OTC switch in 2002 was the largest switch ever--and the first and only for a non-drowsy antihistamine. For more information on allergies and treatment, visit www.CLARITIN.com.

About Schering-Plough

Schering-Plough Consumer Health Care is the U.S. over-the-counter (OTC) and consumer products business unit of Schering-Plough an innovation-driven, science-centered global health care company. Through its own biopharmaceutical research and collaborations with partners, Schering-Plough creates therapies that help save and improve lives around the world. The company applies its research-and-development platform to human prescription, animal health and consumer health care products. Schering-Plough's vision is to "Earn Trust, Every Day" with the doctors, patients, customers and other stakeholders served by its colleagues around the world. The company is based in Kenilworth, N.J., and its Web site is www.schering-plough.com.

SCHERING-PLOUGH DISCLOSURE NOTICE: The information in this press release includes certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to potential market for CLARITIN. Forward-looking statements relate to expectations or forecasts of future events. Schering-Plough does not assume the obligation to update any forward-looking statement. Many factors could cause actual results to differ materially from Schering-Plough's forward-looking statements, including market forces, economic factors, product availability, patent and other intellectual property protection, current and future branded, generic or over-the-counter competition, the regulatory process, and any developments following regulatory approval, among other uncertainties. For further details about these and other factors that may impact the forward-looking statements, see Schering-Plough's Securities and Exchange Commission filings, including Part II, Item 1A. "Risk Factors" in the third quarter 2008 10-Q, filed October 29, 2008.


'/>"/>
SOURCE Schering-Plough
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. New Non-Drowsy CLARITIN(R) Liqui-Gels(R) Now Available
2. FDA Approves Labeling Change for Non-Drowsy CLARITIN(R)
3. TodayMD Renews Race Sponsorship With Alegra Motorsports For A Third Year
4. The American College of Cardiology Renews its Publishing Partnership With Elsevier
5. China Medicine Renews Contract with CCG Investor Relations
6. SEIUs Andy Stern Renews Call to Fix Nations Broken Health Care System, Ease Financial Strain on Working Families, Economy
7. Arthritis Foundation Renews Comprehensive Marketing Contract with Merkle
8. Eisai Renews Its Commitment to Responsible Healthcare Community Interactions in Accordance with the Revised PhRMA Marketing Code
9. AMERIGROUP Renews Contract with Tennessee
10. WHO Report Says 9.7 Million at Risk of Death from AIDS Today; AHF Renews Call for US Congress to Commit to Scale up Treatment to Seven Million Lives
11. Blue Cross Blue Shield of Arizona Renews EDS Information Technology Services Contract
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... QUEENS, N.Y (PRWEB) , ... October 13, 2017 , ... ... recently became a member of ElderCounsel, a national organization of elder law and special ... constantly changing laws and rules. It also provides a forum to network with elder ...
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... The Visiting ... Day Market. Featuring a collection of specialty vendors and unique items from across the ... and quality-focused health and wellness services offered by the VNA. The boutique will ...
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... Yisrayl Hawkins, ... week that explains one of the most popular and least understood books in the ... cryptic and puzzling descriptions that have baffled scholars for centuries. Many have tossed it ...
(Date:10/13/2017)... ... ... “The Journey: From the Mountains to the Mission Field”: the story of a missionary ... Journey: From the Mountains to the Mission Field” is the creation of published author, ... ages and currently teaches a class of ladies at her church, which she has ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... treating sleep apnea using cutting-edge Oventus O2Vent technology. As many as ... disorder characterized by frequent cessation in breathing. Oral appliances can offer significant relief ...
Breaking Medicine News(10 mins):
(Date:9/27/2017)... for their devotion to personalized service, SMP Pharmacy Solutions announces ... the South Florida Business Journal,s 50 Fastest-Growing Companies, and listed ... national specialty pharmacy has found its niche.  To that end, ... honored by SFBJ as the 2017 Power Leader in Health ... his award in October, Bardisa said of the three achievements, ...
(Date:9/25/2017)... 2017   Montrium , an industry leader ... the IQPC Trial Master Files & Inspection Readiness ... EastHORN Clinical Services has selected eTMF Connect ... management. EastHORN, a leading European contract research organization ... transparency to enable greater collaboration with sponsors, improve ...
(Date:9/23/2017)... , Sept. 22, 2017 Janssen Biotech, Inc. ... response letter from the U.S. Food and Drug Administration ... of sirukumab for the treatment of moderately to severely ... additional clinical data are needed to further evaluate the ... severely active RA. ...
Breaking Medicine Technology: